364 related articles for article (PubMed ID: 31460972)
1. Immunotherapy for non-small cell lung cancer.
Vafadar S
JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
[TBL] [Abstract][Full Text] [Related]
2. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
3. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
[No Abstract] [Full Text] [Related]
4. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
[TBL] [Abstract][Full Text] [Related]
6. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
[TBL] [Abstract][Full Text] [Related]
7. Lung cancer in 2016: immunotherapy comes of age.
Mitchell PL; John T
Lancet Respir Med; 2016 Dec; 4(12):947-949. PubMed ID: 27890503
[No Abstract] [Full Text] [Related]
8. Precision Management of Advanced Non-Small Cell Lung Cancer.
Yang CY; Yang JC; Yang PC
Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
13. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
14. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
16. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
Check JH; Check D; Poretta T
Anticancer Res; 2019 Apr; 39(4):1923-1926. PubMed ID: 30952734
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
[TBL] [Abstract][Full Text] [Related]
19. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
Robinson SD; Lai C; Hotton G; Anand G
Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
